Wedbush Initiates Coverage on Aclaris Therapeutics (NASDAQ:ACRS)

Wedbush started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) in a research report report published on Wednesday morning, MarketBeat reports. The firm issued an outperform rating and a $8.00 price target on the biotechnology company's stock. Wedbush also issued estimates for Aclaris Therapeutics' Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.35) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($1.11) EPS.

Other analysts have also recently issued reports about the stock. HC Wainwright restated a "buy" rating and set a $16.00 price target (down from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a report on Tuesday, March 18th. They set an "overweight" rating for the company. Wall Street Zen cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 8th. Finally, Scotiabank decreased their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $9.71.

Aclaris Therapeutics Trading Down 0.7%

Shares of ACRS traded down $0.01 during midday trading on Wednesday, hitting $1.45. The stock had a trading volume of 750,839 shares, compared to its average volume of 1,190,377. Aclaris Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $5.17. The business has a 50-day simple moving average of $1.31 and a two-hundred day simple moving average of $2.17. The firm has a market cap of $157.01 million, a P/E ratio of -2.79 and a beta of 0.42.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. On average, analysts expect that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $26,000. Invesco Ltd. bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $28,000. Graham Capital Management L.P. bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $35,000. Commonwealth Equity Services LLC bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Alpine Global Management LLC bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $38,000. Institutional investors own 98.34% of the company's stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.